Screening all kids 8-18 for anxiety is dumb/dangerous idea: 1)Causes massive false positive overdiagnosis/stigma/misuse of meds 2)Not enough clinicians to treat kids identified 2)Drains resources better used to improve kid's lives/education 3)Neglects dire needs of severely ill

NEJM's "policy about transparency is not particularly transparent, and its policy about limiting the level of conflict of interest for writers of editorials is not enforced" statnews.com/2022/05/19/nej… MEZIS e.V. HealthSense @Spinwatch

The BMJ David Oliver (also on Blue Sky) Joshua D. Wallach Osman Moneer Joseph Ross Most interventions have modest treatment effects. The challenge is to separate modest effects from no effects - hence RCTs. Of course, observational analyses of treatment effects can give you the right answer. But it is impossible to know if they have given you the right answer.

I look forward to the Court's climate policy plans ... they have a life-threatening challenge ahead of them

Moreover, the tri-modal distribution found in this analysis was based on an exploratory analysis. Moreover, this analysis was not able to determine which patients can expect a meaningful drug effect and which not. Thus, we still don't know who this 15% of users are

🚨📣💊Want to work w/ me, Reshma Ramachandran, Matthew Herder (@mattherder.bksy.social), Joseph Ross? Now's your chance! I'm hiring a post-doc in pharma policy, law, and ethics to join me UPenn Medical Ethics & Health Policy. Project will examine the feasibility of post-market trials to confirm drug benefit (and more!). med.upenn.edu/apps/my/bpp_po…

New paper: Many #clinicaltrials fail to inform clinical practice elifesciences.org/articles/79491 @questbih Swiss Clinical Trial Organisation (SCTO)

The proportion of randomized controlled trials that inform clinical practice elifesciences.org/articles/79491 via @KimmelmanJ et al Very disappointing!

The return on investment to the drug industry of FDA user fees is in billions of dollars. PDUFA is all about how fast can FDA approve drugs, and not about if they help patients. FDA Drug Information F.D.A.’s Drug Industry Fees Fuel Concerns Over Influence nytimes.com/2022/09/15/hea…

Agree, agree, agree!

Today the The New York Times is publishing the first two installments in a series called "Profits Over Patients." It's about how tax-exempt hospitals have strayed from their charitable missions for the sake of fatter profits – with profound consequences for the US healthcare system. 🧵

And the sky is blue. What say you U.S. FDA?

3. AMX0035: 1 study, stat sig results re: fxnl decline on co's analysis not FDA's, survival benefit in OLE I get excitement for another option+hope this 1 works. But note this is the assortment of tx options produced by low FDA approval standards. 2/2 accessdata.fda.gov/scripts/cder/d…

The newly approved ALS drug is overpriced and may not work. Otherwise the FDA is doing great! Lisa Jarvis bloomberg.com/opinion/articl… via Bloomberg Opinion

Seems like a terrible idea. We want Congress to give regulatory agencies the authority to make decisions - esp those that impact public health - using best science/evidence, not to be hamstrung when Congress is unhappy with the decisions. pharmaphorum.com/?p=99430 via pharmaphorum

Great exposé of the Medicare Advantage grift. Any wonder that the "hottest" heath care startups are just fancy MA plans? Fraud in MA could be as large as the budget of the FBI, EPA and federal prison system combined. thanks Margot Sanger-Katz Reed Abelson nytimes.com/2022/10/08/ups…

Belfast and Edinburgh reduced their speed limits from 30 mph to 20. The result: "The main outcome of these schemes was a reduction in road casualties at all levels of severity." pubmed.ncbi.nlm.nih.gov/36173872/

U.S. Senators demand rapid disclosure of all NIH clinical trial results -> finally policy makers are waking up to the immense cost of federally funded research waste in medicine transparimed.org/single-post/se…

TranspariMED Deborah Zarin FDA Commissioner

So last week I was at CHEST, a meeting of respiratory docs and < 5% in masks. Now I am at #SMDM22 , a meeting of experts in tradeoffs, spillover effects and social welfare, and 90 pct in masks. I feel like there is a learning here.